Blijlevens NM - Search Results

1

Targeting the IL17 pathway for the prevention of graft-versus-host disease.

van der Waart AB, van der Velden WJ, Blijlevens NM, Dolstra H. van der Waart AB, et al. Among authors: blijlevens nm. Biol Blood Marrow Transplant. 2014 Jun;20(6):752-9. doi: 10.1016/j.bbmt.2014.02.007. Epub 2014 Feb 22. Biol Blood Marrow Transplant. 2014. PMID: 24565991 Free article. Review.

2

Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview.

Blijlevens NM, Donnelly JP, De Pauw BE. Blijlevens NM, et al. Bone Marrow Transplant. 2000 Jun;25(12):1269-78. doi: 10.1038/sj.bmt.1702447. Bone Marrow Transplant. 2000. PMID: 10871732 Free PMC article. Review.

3

Primary hepatic invasive aspergillosis with progression after rituximab therapy for a post transplantation lymphoproliferative disorder.

van der Velden WJ, Blijlevens NM, Klont RR, Donnelly JP, Verweij PE. van der Velden WJ, et al. Among authors: blijlevens nm. Ann Hematol. 2006 Sep;85(9):621-3. doi: 10.1007/s00277-006-0129-x. Epub 2006 Jun 7. Ann Hematol. 2006. PMID: 16758192

4

Cyclosporine short infusion and C2 monitoring in haematopoietic stem cell transplant recipients.

Hendriks MP, Blijlevens NM, Schattenberg AV, Burger DM, Donnelly JP. Hendriks MP, et al. Among authors: blijlevens nm. Bone Marrow Transplant. 2006 Oct;38(7):521-5. doi: 10.1038/sj.bmt.1705481. Bone Marrow Transplant. 2006. PMID: 16981000 Clinical Trial.

5

The potential role of lactoferrin and derivatives in the management of infectious and inflammatory complications of hematology patients receiving a hematopoietic stem cell transplantation.

van der Velden WJ, Blijlevens NM, Donnelly JP. van der Velden WJ, et al. Among authors: blijlevens nm. Transpl Infect Dis. 2008 Apr;10(2):80-9. doi: 10.1111/j.1399-3062.2007.00260.x. Epub 2007 Jul 1. Transpl Infect Dis. 2008. PMID: 17605731 Review.

6

[Invasive zygomycosis in patients treated for haematological malignancies].

Verweij PE, van der Velden WJ, Donnelly JP, Blijlevens NM, Warris A. Verweij PE, et al. Among authors: blijlevens nm. Ned Tijdschr Geneeskd. 2007 Nov 24;151(47):2597-602. Ned Tijdschr Geneeskd. 2007. PMID: 18161258 Dutch.

7

Palifermin in allogeneic HSCT: many questions remain.

van der Velden WJ, Herbers AH, Blijlevens NM. van der Velden WJ, et al. Among authors: blijlevens nm. Bone Marrow Transplant. 2009 Jan;43(1):85-6. doi: 10.1038/bmt.2008.269. Epub 2008 Sep 1. Bone Marrow Transplant. 2009. PMID: 18762763 No abstract available.

8

Febrile mucositis in haematopoietic SCT recipients.

van der Velden WJ, Blijlevens NM, Feuth T, Donnelly JP. van der Velden WJ, et al. Among authors: blijlevens nm. Bone Marrow Transplant. 2009 Jan;43(1):55-60. doi: 10.1038/bmt.2008.270. Epub 2008 Sep 1. Bone Marrow Transplant. 2009. PMID: 18762766

9

Palifermin-induced flexural hyperpigmentation: a clinical and histological study of five cases.

Sibelt LA, Aboosy N, van der Velden WJ, Blijlevens NM, Blokx WA, Seyger MM. Sibelt LA, et al. Among authors: blijlevens nm. Br J Dermatol. 2008 Nov;159(5):1200-3. doi: 10.1111/j.1365-2133.2008.08816.x. Epub 2008 Sep 15. Br J Dermatol. 2008. PMID: 18795935

10

NOD2 polymorphisms predict severe acute graft-versus-host and treatment-related mortality in T-cell-depleted haematopoietic stem cell transplantation.

van der Velden WJ, Blijlevens NM, Maas FM, Schaap NP, Jansen JH, van der Reijden BA, Feuth T, Dolstra H, Donnelly JP. van der Velden WJ, et al. Among authors: blijlevens nm. Bone Marrow Transplant. 2009 Aug;44(4):243-8. doi: 10.1038/bmt.2009.21. Epub 2009 Feb 16. Bone Marrow Transplant. 2009. PMID: 19219079

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

286 results

Search Page

Filters